


P20854.A01

REMARKS

By the above amendment, the claims have been amended to delete multiple dependency.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,  
Hiroshi SHIKU et al.

  
Bruce H. Bernstein  
Reg. No. 29,027


March 30, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

09787945-070901

MARKED-UP COPY OF AMENDED CLAIMS

3. (Amended) The cell according to claim 1 [or 2], characterized in that the hydrophobized polysaccharide is a polysaccharide modified with an alkyl group or a sterol residue.

4. (Amended) The cell according to [any one of claims 1 to 3] claim 1, wherein the hydrophobized polysaccharide is a polysaccharide characterized to contain a saccharide unit, at a ratio of 0.5 to 5 in average per 100 saccharide units that constitute the polysaccharide, whose primary hydroxyl group is a group represented by the formula:



wherein R represents an alkyl group or a sterol residue; m represents 0 or 1; and n represents a positive integer.

5. (Amended) The cell according to claim 3 [or 4], characterized in that the sterol residue is cholesterol residue.

6. (Amended) The cell according to [any one of claims 1 to 5] claim 1, characterized in that the polysaccharide is pullulan or mannan.

7. (Amended) The cell according to [any one of claims 1 to 6] claim 1, characterized in that the antigen is a protein which is presented as an oligopeptide by an MHC class I antigen, and induces a cytotoxic T-cell.

10. (Amended) The cell according to [any one of claims 1 to 9] claim 1, which is characterized to be used as a medicament for parenteral administration.

P20854.A01

12 (Amended) The method according to claim 11 [or 12] characterized in that an amount of the complex comprising a hydrophobized polysaccharide and an antigen is sufficient to induce cellular immunity.

09787916-070901